Equities analysts predict that Leap Therapeutics, Inc. (NASDAQ:LPTX – Get Rating) will post ($0.11) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Leap Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.13). Leap Therapeutics posted earnings per share of ($0.12) in the same quarter last year, which suggests a positive year over year growth rate of 8.3%. The company is scheduled to issue its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Leap Therapeutics will report full-year earnings of ($0.45) per share for the current fiscal year, with EPS estimates ranging from ($0.49) to ($0.41). For the next year, analysts expect that the company will post earnings of ($0.51) per share, with EPS estimates ranging from ($0.61) to ($0.39). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Leap Therapeutics.
Leap Therapeutics (NASDAQ:LPTX – Get Rating) last issued its quarterly earnings data on Friday, March 11th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. Leap Therapeutics had a negative net margin of 2,705.80% and a negative return on equity of 55.42%.
Shares of NASDAQ:LPTX opened at $1.59 on Friday. The firm has a 50 day moving average of $1.88 and a 200-day moving average of $2.42. The stock has a market capitalization of $140.43 million, a PE ratio of -3.31 and a beta of 0.56. Leap Therapeutics has a 12 month low of $1.33 and a 12 month high of $4.17.
Several institutional investors have recently bought and sold shares of LPTX. FMR LLC increased its position in Leap Therapeutics by 63.3% during the 1st quarter. FMR LLC now owns 1,563,124 shares of the company’s stock valued at $2,923,000 after purchasing an additional 606,000 shares during the period. Morgan Stanley increased its position in Leap Therapeutics by 426,666.7% during the 1st quarter. Morgan Stanley now owns 38,409 shares of the company’s stock valued at $73,000 after purchasing an additional 38,400 shares during the period. Citadel Advisors LLC acquired a new stake in Leap Therapeutics during the 2nd quarter valued at approximately $53,000. International Assets Investment Management LLC acquired a new stake in Leap Therapeutics during the 3rd quarter valued at approximately $40,000. Finally, Valeo Financial Advisors LLC acquired a new stake in Leap Therapeutics during the 3rd quarter valued at approximately $52,000. 61.55% of the stock is currently owned by institutional investors.
About Leap Therapeutics (Get Rating)
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.
- Get a free copy of the StockNews.com research report on Leap Therapeutics (LPTX)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- UiPath Stock is Nearing Rock Bottom Down Here
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.